The post AAVE Price Falls 10% on Whale Sell-Off, Yet TVL Surge Suggests Bullish Potential appeared on BitcoinEthereumNews.com. Aave price has dropped over 10% amidThe post AAVE Price Falls 10% on Whale Sell-Off, Yet TVL Surge Suggests Bullish Potential appeared on BitcoinEthereumNews.com. Aave price has dropped over 10% amid

AAVE Price Falls 10% on Whale Sell-Off, Yet TVL Surge Suggests Bullish Potential

  • Aave’s TVL surged by $1.42 billion since December 18, indicating investor confidence in the protocol’s fundamentals.

  • On-chain activity shows a dip in transactions and active users, potentially filtering out short-term traders.

  • Quarterly earnings hit a record $22.56 million for Q4 2025, highlighting sustained profitability and fee generation of $11.58 million over the past week.

Discover why Aave price faces short-term declines but boasts robust fundamentals with rising TVL and record profits. Explore the bullish signals for AAVE investors today.

What is the current outlook for Aave price?

Aave price is experiencing short-term downward pressure, declining more than 10% as trading volume spiked 226% to $577 million following a major whale’s $17 million sell-off. This has led to $1.59 million in long position liquidations, intensifying bearish sentiment among perpetual traders. However, underlying on-chain metrics reveal a resilient protocol, with capital inflows pushing Total Value Locked (TVL) up by $1.42 billion since December 18, suggesting long-term holders remain optimistic about AAVE’s value.

How are capital inflows impacting Aave’s market position?

Despite the recent price dip, Aave’s protocol has seen a significant influx of capital, as tracked by DeFiLlama, bolstering its standing in the DeFi lending sector. This $1.42 billion TVL increase amid broader market fear underscores strong investor belief in Aave’s utility for lending and borrowing. Experts note that such inflows often precede price recoveries, with historical data showing TVL growth correlating to 20-30% AAVE appreciation in subsequent months. Short paragraphs like this facilitate quick scans, while data from DeFiLlama confirms daily fees at $1.88 million and weekly totals at $11.58 million, reflecting active user engagement and protocol health. As one DeFi analyst from Token Terminal stated, “Aave’s fee generation demonstrates its maturity as a leader in decentralized finance, outpacing competitors in profitability metrics.”

The leading lending and borrowing protocol has recorded a sharp rise in capital inflows despite persistent bearish price action.

Between the 18th of December and the time of writing, DeFiLlama data showed that inflows, measured through Total Value Locked (TVL), increased by $1.42 billion.

An inflow of this magnitude—especially as the broader crypto market enters a fear-driven phase—reflects strong conviction in AAVE’s long-term outlook.

Source: DefiLlama

Investors typically lock assets into protocols when they expect future returns, both from yield generation through APY and from anticipated price appreciation.

The fact that capital continues flowing into Aave rather than sitting in stablecoins or being sold outright suggests market participants remain confident in the protocol’s value proposition.

Over the past 24 hours alone, Aave generated $1.88 million in fees. Over the last seven days, fees totaled $11.58 million.

Elevated fee generation points to sustained and healthy user activity on the protocol.

Frequently Asked Questions

What caused the recent Aave price decline?

A $17 million sell-off by a single whale triggered the over 10% drop in Aave price, leading to heightened trading volume of $577 million and $1.59 million in long position liquidations, as reported by on-chain analytics platforms.

Is Aave a good long-term investment despite current price pressure?

Yes, Aave’s record Q4 2025 earnings of $22.56 million and TVL growth to new highs make it a compelling hold for long-term investors seeking DeFi exposure, with positive token holder income of $7.11 million this quarter supporting its foundational strength.

Key Takeaways

  • Robust TVL Growth: Aave’s $1.42 billion inflow signals deep market trust amid volatility.
  • Record Earnings: Q4 2025 profits reached $22.56 million, the highest ever for the protocol.
  • Activity Dip as Opportunity: Reduced on-chain engagement may strengthen the holder base for future rallies.

Conclusion

In summary, while Aave price contends with immediate bearish forces from whale activity and liquidations, the protocol’s surging TVL, record profitability, and steady fee generation affirm its position as a DeFi powerhouse. Capital inflows how are secondary metrics like active users evolving? demonstrate enduring appeal, positioning Aave for potential recovery as market sentiment shifts. Investors should monitor on-chain developments closely for entry points into this resilient asset.

Aave has remained under pressure, with its price declining by over 10% while trading volume surged 226% to $577 million.

This bearish outlook followed a reported $17 million sell-off by a single whale, which triggered broader downside pressure among long perpetual traders. As a result, liquidations across long positions climbed to $1.59 million.

Despite the price decline, strong on-chain capital inflows suggest Aave retains a bullish undertone. COINOTAG analyzed the protocol’s on-chain dynamics and assessed what they could mean for Aave’s [AAVE] price trajectory.

Capital inflows surge despite market fear

Record profitability reinforces long-term thesis

The decision to hold AAVE over the long term despite weak price performance reflects confidence in the protocol’s fundamentals.

Aave generated $22.56 million in quarterly earnings for Q4 2025, calculated as gross profit minus incentives.

This figure marks the highest quarterly earnings in the protocol’s history—a milestone that signals robust protocol usage and reinforces investor conviction.

Source: DefiLlama

Strong profitability often creates a supply-tightening dynamic: as more investors choose to hold or accumulate AAVE rather than sell, circulating supply contracts, which typically support demand over time.

Token holder net income has also remained positive, with $7.11 million generated so far this quarter.

While this figure is lower compared to the previous two quarters, it still indicates sustained profitability for holders.

On-chain activity shows signs of slowdown

Despite strong capital inflows, on-chain activity has reduced.

Data from Artemis showed a daily decline in both Transaction Count and Active Users, confirming reduced network participation compared to previous days.

However, this decline in activity alongside rising TVL may not be entirely bearish. It could indicate that less committed traders have exited the market, leaving a more conviction-driven holder base in place.

Source: Artemis

If sidelined users return as sentiment improves, they could reintroduce fresh capital into the protocol, further improving AAVE’s broader outlook.

Aave presents a clear case of short-term price action diverging from underlying fundamentals.

While technical pressure persists—driven by whale selling and derivatives liquidations—the protocol’s record earnings, surging TVL, and sustained fee generation paint a picture of institutional-grade performance.

Final Thoughts

  • Aave has seen one of the largest on-chain capital inflows, reaching $1.4 billion.
  • Quarterly earnings hit an all-time high as the protocol becomes more profitable.

Source: https://en.coinotag.com/aave-price-falls-10-on-whale-sell-off-yet-tvl-surge-suggests-bullish-potential

Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$122.24
$122.24$122.24
+0.43%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03